Stock data
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV) reported net income of -US$77.91M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$84.11M | -US$77.91M | — |
| 2024 | — | — | -US$89.20M | -US$80.56M | — |
| 2023 | — | — | -US$67.10M | -US$60.39M | — |
| 2022 | — | — | -US$32.66M | -US$31.17M | — |
| 2021 | — | — | -US$16.18M | -US$16.24M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$17.96M | — |
| 2026-03-31 | — | -US$19.04M | — |
| 2025-12-31 | — | -US$18.98M | — |
| 2025-09-30 | — | -US$18.23M | — |
| 2025-06-30 | — | -US$21.01M | — |
| 2025-03-31 | — | -US$19.68M | — |
| 2024-12-31 | — | -US$22.83M | — |
| 2024-09-30 | — | -US$22.44M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.